-
Something wrong with this record ?
Interrogating open issues in cancer precision medicine with patient-derived xenografts
AT. Byrne, DG. Alférez, F. Amant, D. Annibali, J. Arribas, AV. Biankin, A. Bruna, E. Budinská, C. Caldas, DK. Chang, RB. Clarke, H. Clevers, G. Coukos, V. Dangles-Marie, SG. Eckhardt, E. Gonzalez-Suarez, E. Hermans, M. Hidalgo, MA. Jarzabek, S....
Nature reviews. Cancer.
2017 ;
17 (4) :
254-268.
[pub] 20170120
Language English Country England, Great Britain
Document type Journal Article, Review
Persistent link
https://www.medvik.cz/link/bmc17023345
Online
Full text
NLK
ProQuest Central
from 2001-10-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2001-10-01 to 1 year ago
Health & Medicine (ProQuest)
from 2001-10-01 to 1 year ago
Family Health Database (ProQuest)
from 2001-10-01 to 1 year ago
Public Health Database (ProQuest)
from 2001-10-01 to 1 year ago
PubMed
28104906
DOI
10.1038/nrc.2016.140
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Neoplasm MeSH
- Immunotherapy MeSH
- Precision Medicine * MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Disease Models, Animal MeSH
- Mice MeSH
- Biomarkers, Tumor analysis MeSH
- Neoplastic Stem Cells physiology MeSH
- Neoplasms pathology therapy MeSH
- Xenograft Model Antitumor Assays * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.
CIBERONC 08035 Barcelona Spain
EurOPDX Consortium and are at the Katholieke Universiteit Leuven 3000 Leuven Belgium
EurOPDX Consortium and are at the Royal College of Surgeons in Ireland Dublin 2 Ireland
Seeding Science SAS 75020 Paris France
University of Colorado Cancer Center Aurora Colorado 80045 USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023345
- 003
- CZ-PrNML
- 005
- 20170908105349.0
- 007
- ta
- 008
- 170720s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/nrc.2016.140 $2 doi
- 035 __
- $a (PubMed)28104906
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Byrne, Annette T $u EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
- 245 10
- $a Interrogating open issues in cancer precision medicine with patient-derived xenografts / $c AT. Byrne, DG. Alférez, F. Amant, D. Annibali, J. Arribas, AV. Biankin, A. Bruna, E. Budinská, C. Caldas, DK. Chang, RB. Clarke, H. Clevers, G. Coukos, V. Dangles-Marie, SG. Eckhardt, E. Gonzalez-Suarez, E. Hermans, M. Hidalgo, MA. Jarzabek, S. de Jong, J. Jonkers, K. Kemper, L. Lanfrancone, GM. Mælandsmo, E. Marangoni, JC. Marine, E. Medico, JH. Norum, HG. Palmer, DS. Peeper, PG. Pelicci, A. Piris-Gimenez, S. Roman-Roman, OM. Rueda, J. Seoane, V. Serra, L. Soucek, D. Vanhecke, A. Villanueva, E. Vinolo, A. Bertotti, L. Trusolino,
- 520 9_
- $a Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a nádory $x patologie $x terapie $7 D009369
- 650 _2
- $a nádorové kmenové buňky $x fyziologie $7 D014411
- 650 12
- $a individualizovaná medicína $7 D057285
- 650 12
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Alférez, Denis G $u EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK. $7 gn_A_00004082
- 700 1_
- $a Amant, Frédéric $u EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium. The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. $7 gn_A_00005251
- 700 1_
- $a Annibali, Daniela $u EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium. $7 gn_A_00007139
- 700 1_
- $a Arribas, Joaquín $u EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain. CIBERONC, 08035 Barcelona, Spain. $7 gn_A_00008866
- 700 1_
- $a Biankin, Andrew V $u EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
- 700 1_
- $a Bruna, Alejandra $u EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
- 700 1_
- $a Budinská, Eva $u EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
- 700 1_
- $a Caldas, Carlos $u EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
- 700 1_
- $a Chang, David K $u EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
- 700 1_
- $a Clarke, Robert B $u EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
- 700 1_
- $a Clevers, Hans $u Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
- 700 1_
- $a Coukos, George $u EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
- 700 1_
- $a Dangles-Marie, Virginie $u EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
- 700 1_
- $a Eckhardt, S Gail $u University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
- 700 1_
- $a Gonzalez-Suarez, Eva $u EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
- 700 1_
- $a Hermans, Els $u EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
- 700 1_
- $a Hidalgo, Manuel $u EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
- 700 1_
- $a Jarzabek, Monika A $u EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
- 700 1_
- $a de Jong, Steven $u EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
- 700 1_
- $a Jonkers, Jos $u EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
- 700 1_
- $a Kemper, Kristel $u EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
- 700 1_
- $a Lanfrancone, Luisa $u EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
- 700 1_
- $a Mælandsmo, Gunhild Mari $u EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
- 700 1_
- $a Marangoni, Elisabetta $u EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
- 700 1_
- $a Marine, Jean-Christophe $u EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
- 700 1_
- $a Medico, Enzo $u EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
- 700 1_
- $a Norum, Jens Henrik $u EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
- 700 1_
- $a Palmer, Héctor G $u EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
- 700 1_
- $a Peeper, Daniel S $u EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
- 700 1_
- $a Pelicci, Pier Giuseppe $u EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
- 700 1_
- $a Piris-Gimenez, Alejandro $u EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
- 700 1_
- $a Roman-Roman, Sergio $u EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
- 700 1_
- $a Rueda, Oscar M $u EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
- 700 1_
- $a Seoane, Joan $u CIBERONC, 08035 Barcelona, Spain.
- 700 1_
- $a Serra, Violeta $u EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
- 700 1_
- $a Soucek, Laura $u EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
- 700 1_
- $a Vanhecke, Dominique $u EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
- 700 1_
- $a Villanueva, Alberto $u EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
- 700 1_
- $a Vinolo, Emilie $u Seeding Science SAS, 75020 Paris, France.
- 700 1_
- $a Bertotti, Andrea $u EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
- 700 1_
- $a Trusolino, Livio $u EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland. EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
- 773 0_
- $w MED00007084 $t Nature reviews. Cancer $x 1474-1768 $g Roč. 17, č. 4 (2017), s. 254-268
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28104906 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170908105950 $b ABA008
- 999 __
- $a ok $b bmc $g 1239026 $s 984258
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 4 $d 254-268 $e 20170120 $i 1474-1768 $m Nature reviews. Cancer $n Nat Rev Cancer $x MED00007084
- LZP __
- $a Pubmed-20170720
